Vasculitis & polymyalgia rheumatica
Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis
Authors' conclusion
In this study of patients with AAV primarily treated with RTX, redGC was associated with an increased risk of the primary outcome consisting of death, ESKD, AAV progression before remission or relapse.
Study context
- Population
- Patients with ANCA-associated vasculitis (AAV) (GPA and MPA), primarily treated with rituximab (RTX)
- Participants
- 234 patients
- Exposure
- PEXIVAS reduced-dose GC regimen vs standard-dose GC regimen
- redGCn = 126
- standGCn = 108reference
- Outcome
- Composite of:
- Death
- ESKD
- AAV progression before remission
- Relapse
- Follow-up
- 12 months following induction
Methodological detailsmulticentre, inverse probability of treatment weighting
- Multicentre
- Inverse probability of treatment weighting
Main finding
As reported in the abstract
12 months
Observational data: associations, not effects.
Further findings
Primary outcome by serum creatinine among redGC-treated (subgroup)
- Serum creatinine>300 µmol/L more likely to achieve the primary outcome
Death or end-stage kidney disease (ESKD) and primary outcome in RTX-treated (subgroup)
- RTX-treated receiving redGC more likely to experience death or ESKD and to achieve the primary outcome
Original publication
Real-life use of the PEXIVAS reduced-dose glucocorticoid regimen in granulomatosis with polyangiitis and microscopic polyangiitis. Ann Rheum Dis. Published 2 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →